INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 245 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,416,513 | -22.1% | 44,798 | +0.5% | 0.00% | 0.0% |
| Q2 2023 | $1,817,932 | +26.4% | 44,579 | +15.5% | 0.00% | 0.0% |
| Q1 2023 | $1,437,914 | +14.5% | 38,581 | +7.2% | 0.00% | 0.0% |
| Q4 2022 | $1,255,726 | -43.6% | 35,991 | -9.5% | 0.00% | -50.0% |
| Q3 2022 | $2,225,000 | +2.8% | 39,767 | -4.9% | 0.00% | 0.0% |
| Q2 2022 | $2,165,000 | -27.2% | 41,823 | +2.2% | 0.00% | -33.3% |
| Q1 2022 | $2,973,000 | -43.7% | 40,911 | -8.4% | 0.00% | -25.0% |
| Q4 2021 | $5,279,000 | -10.1% | 44,643 | +2.0% | 0.00% | -33.3% |
| Q3 2021 | $5,869,000 | -13.6% | 43,752 | +4.3% | 0.01% | -14.3% |
| Q2 2021 | $6,790,000 | +57.4% | 41,935 | -22.0% | 0.01% | +40.0% |
| Q1 2021 | $4,315,000 | +83.1% | 53,761 | +24.1% | 0.01% | +66.7% |
| Q4 2020 | $2,356,000 | +284.3% | 43,307 | +40.4% | 0.00% | +200.0% |
| Q3 2020 | $613,000 | +10.3% | 30,847 | +16.7% | 0.00% | 0.0% |
| Q2 2020 | $556,000 | +278.2% | 26,441 | +119.8% | 0.00% | – |
| Q1 2020 | $147,000 | – | 12,032 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |